Dear Editor, Translocations involving chromosomal band 11q23 are found in most of the infant acute lymphoblastic leukemia and in acute myeloblastic leukemia. The majority of these translocations lead to the rearrangement of the MLL gene and the formation of new chimeric genes [1] . We report here a case of congenital acute monoblastic leukemia and myeloid sarcoma associated with an apparent t(1;11)(p36; q23) which proved to be in fact a complex 1;19;11 translocation.
Dear Editor, Translocations involving chromosomal band 11q23 are found in most of the infant acute lymphoblastic leukemia and in acute myeloblastic leukemia. The majority of these translocations lead to the rearrangement of the MLL gene and the formation of new chimeric genes [1] . We report here a case of congenital acute monoblastic leukemia and myeloid sarcoma associated with an apparent t(1;11)(p36; q23) which proved to be in fact a complex 1;19;11 translocation.
This female child was born after a pregnancy of 33 weeks and 6 days complicated by gravidic toxemia and hydramnios. At birth, the baby was cyanosed and showed no reaction to stimuli. She had disseminated intravascular coagulation with petechiae and hematoma on the neck and the limbs. Cutaneous tumors were observed on the abdomen, the right arm and the left thigh. Her hematological data were as follows: hemoglobin 14 g/dl, white blood cells (WBC) 162×10 9 /L with 0.5% neutrophils, 0.5% eosinophils, 9.5% lymphocytes, 8% monocytes and 80% monoblasts and promonocytes, and platelets 50×10 9 /L. A diagnosis of acute monoblastic leukemia (FAB type M5) was made. The biopsy of one cutaneous tumor showed a massive derma infiltration by monoblasts; therefore, these skin tumors were considered to be myeloid sarcomas. Palliative care solely was applied. The child developed acute renal insufficiency and massive cerebral hemorrhage, of which she died 24 h after birth [2] .
Cytogenetic analysis was performed on bone marrow cells with standard techniques. We observed a translocation which appeared to be balanced in R-banding between chromosomes 1 and 11; thus, the karyotype was written as 46,XX,t(1;11)(p36.2;q23). FISH analysis using the LSI MLL dual color probe (Abbott, Rungis, France) confirmed the disruption of the MLL gene. It showed the translocation of the 3′ region of MLL (red signal) to the derivative chromosome 1 while the 5′ region (green signal) remained on the der(11).
We then used long-distance inverse PCR (LDI-PCR) to identify the MLL fusion partner involved in the chromosomal translocation of that particular patient [3] . Genomic DNA was isolated from methanol/acetic acid-fixed cells of leukemia patient that were stored at −20°C. DNA was extracted using the QIAamp DNA mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer recommendations. After DNA digestion, resulting DNA fragments were re-ligated to form DNA circles prior to LDI-PCR studies. LDI-PCR reactions were performed as Ann Hematol (2009) [3] and according to the recommendations of the manufacturer (Triple Master Kit, Eppendorf). PCR amplimers were cut off the gel and subjected to sequence analyses (Fig. 1a, left panel) . Sequence analysis revealed that the 5′ region of MLL (break in intron 9) was fused in-frame with the 3′ region of ELL (break in intron 5), a gene located in chromosomal band 19p13.11.
Since cytogenetic analysis revealed a 46,XX,t(1;11) (p36.2;q23) karyotype, however, the MLL gene was fused to the ELL gene located on chromosome 19p13.11, we started to re-investigate the genomic rearrangement in more detail by using a combination of two BAC clones. The first one, RP11-937I20 (labeled in Spectrum orange), spans the ELL gene, and the second one, RP11-91A14, (labeled in FITC), covers the MLL gene. Two green signals (one on the normal chromosome 11 and one on the der(1)), two red signals (one on the normal chromosome 19 and one on the der(19)) and one yellow signal on the der(11) were seen (Fig. 2) . These data confirmed a complex MLL rearrangement, involving loci at 1p36, 11q23 and 19p13.11. In order to clarify its true nature, FISH using subtelomeric probes for chromosomes 1 and 19 (Abbott, Rungis, France) was performed. It showed the presence of 1p subtelomeric sequences on chromosome 19 and of 19p subtelomeric sequences on chromosome 11. Therefore, we reclassified the chromosomal abnormality as a three-way translocation, t(1;19;11)(p36;p13.11;q23).
To verify the MLL-ELL fusion on a more functional level, total RNA was also isolated from methanol/aceticacid-fixed cells with RNeasy Mini kit (Qiagen), then reverse transcribed with Omniscript Reverse transcription kit (Qiagen) [4] . The MLL forward primer was: 5′-CAGAGCAGAGCAAACAGAAAA-3′ and ELL reverse primer was: 5′-CTCTCCGTGCTCACAGTCTC-3′. The MLL-ELL transcript fusion was amplified by HotStarTaq polymerase (Qiagen) with these conditions (Applied Biosystems 9700): 15 min at 95°C; 35 cycles at 94°C for 30 s, 58°C for 45 s and 72°C for 1 min 30 s; extension at 72°C for 5 min. PCR products were analyzed on a 2% agarose gel and visualized by ethidium bromide staining. Thus, the genomic MLL-ELL fusion gene is readily expressed and the presence of the resulting MLL-ELL fusion mRNA was confirmed in the patient cells (Fig. 1, right panel) .
Several attempts to identify the missing two other fusion alleles (a gene located at 1p36 fused to ELL, MLL fused to a gene located at 1p36) failed so far, although we tested thoroughly for it. This might be due to ligation products, Fig. 1 Molecular analyses. The DNA sample was treated and analyzed as described. Briefly, 1 µg of genomic DNA was digested with restriction enzymes and re-ligated to form DNA circles before LDI-PCR using MLL-specific primers. Restriction polymorphic PCR amplimers were isolated from the gel and subjected to DNA sequence analyses to obtain the patient-specific fusion sequences. (1) is giving a green signal, der(19) a red signal and der(11) a yellow signal used as template for LDI-PCR experiments, which were too long to obtain appropriate PCR amplimers. Another explanation might be that this complex translocation was accompanied by deletion events that resulted in loss of primer binding sites necessary to generate PCR amplimers. Thus, FISH probes may still be able to bind, but PCR experiments remained negative.
The ELL gene (19p13.11) is frequently identified in MLL-rearranged leukemia patients (~5%) [5] and associated with the development of acute myeloblastic leukemia. MLL-ELL fusions are described in childhood (~11%) and adult (9%) AML patients [6] . Noteworthy is that MLL-ELL fusion has a peak incidence in elderly childhood and adult AML patients. MLL-ELL is also frequently identified in secondary AML patients where MLL-ELL fusion displays an overall frequency of about 30% [7] . The combination of molecular and FISH techniques allowed the chromosomal rearrangement observed in our patient to be classified as a three-way translocation, t(1;19;11)(p36;p13.11;q23), with one MLL-ELL fusion allele. This new abnormality might be considered as a complex t(11;19), which was undetected in conventional cytogenetics and resulted in a severe "prenatal AML" disease phenotype.
From the presented data, the following conclusions can be drawn: (1) the analyzed patient contains, as demonstrated by FISH, three independent chromosomal fusion sites involving the chromosomal regions 1p36, 11q23 and 19p13.11; (2) although the sole fusion between 11q23 (MLL) and 19p13.11 (ELL) was successfully analyzed at the DNA and RNA level, we assume that there are additional mutations that resulted in the severe prenatal AML disease phenotype; (3) these mutations may include yet unknown gene fusions (gain-of-function) or deletion of tumor suppressor genes (loss-of-function) located in either of these chromosomal regions. As a matter of fact, several interesting candidate genes are located at 1p36, as e.g. HES4 (hairy and enhancer of split 4), CCNL2 (cyclin L2), VWA1 (von Willebrand factor A domain containing 1), HES5 (hairy and enhancer of split 5), WDR8 (WD repeat domain 8), TP73 (tumor protein p73), HES3 (hairy and enhancer of split 3), CASP9 (caspase 9, apoptosis-related cysteine peptidase), RUNX3 (runt-related transcription factor 3) and ID3 (inhibitor of DNA binding 3, dominant negative helix-loop-helix protein). Further work focusing on that 1p36 region will presumably unravel the underlying genetic mechanisms in that particular leukemia patient. This will allow drawing conclusions on synergistic mutations for MLL rearrangements.
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